Cellosaurus logo
expasy logo

Cellosaurus PC9-OR#1 (CVCL_D7FL)

[Text version]
Cell line name PC9-OR#1
Accession CVCL_D7FL
Resource Identification Initiative To cite this cell line use: PC9-OR#1 (RRID:CVCL_D7FL)
Comments Population: Chinese; Han and Japanese.
Characteristics: The parent cell line transiently expressing the luciferase gene was injected into the leptomeningeal space of SHO mice, after which the mice were treated daily with osimertinib. After continuous treatment with osimertinib for 2 weeks, the mice developed osimertinib resistance and were subsequently treated daily with osimertinib for 2 weeks (PubMed=34145930).
Selected for resistance to: ChEBI; CHEBI_90943; Osimertinib (AZD9291).
Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
Sequence variations
  • Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
Disease Lung adenocarcinoma (NCIt: C3512)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_B260 (PC-9)
Sex of cell Male
Age at sampling 45Y
Category Cancer cell line
Publications

PubMed=34145930; DOI=10.1111/cas.15035; PMCID=PMC8409422
Fukuda K., Otani S., Takeuchi S., Arai S., Nanjo S., Tanimoto A., Nishiyama A., Naoki K., Yano S.
Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Cancer Sci. 112:3784-3795(2021)

Entry history
Entry creation10-Sep-2024
Last entry update19-Dec-2024
Version number2